title: Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
authors.forename: N S
authors.initials: NS
authors.lastname: Kirkby
authors.forename: P D M
authors.initials: PD
authors.lastname: Leadbeater
authors.forename: M V
authors.initials: MV
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Nylander
authors.forename: J A
authors.initials: JA
authors.lastname: Mitchell
authors.forename: T D
authors.initials: TD
authors.lastname: Warner
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D006801:Humans; D010879:Piperazines / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*; D013876:Thiophenes / Q000494:pharmacology*; D000077486:Ticagrelor
chemical_list: C548576:P2RY12 protein, human; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D001241:Aspirin